Warning: fopen(/home/virtual/jptm/journal/upload/ip_log/ip_log_2023-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Journal of Pathology and Translational Medicine
Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine



Page Path
HOME > J Pathol Transl Med > Volume 47(1); 2013 > Article
Original Article
Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes
Joo-Yeun Kim,, Na Ri Shin,, Ahrong Kim, Hyun-Jeong Lee, Won-young Park, Jee-Yeon Kim, Chang-Hun Lee, Gi-Young Huh1, Do Youn Park
Korean Journal of Pathology 2013;47(1):28-35.
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.28
Published online: February 25, 2013
  • 87 Download
  • 54 Crossref
  • 59 Scopus

Department of Pathology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

1Department of Forensic Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

Corresponding Author: Do Youn Park, M.D. Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: +82-51-240-7717, Fax: +82-51-256-0788, pdy220@pusan.ac.kr
*Joo-Yeun Kim and Na Ri Shin contributed equally to this work.
• Received: October 25, 2012   • Revised: December 27, 2012   • Accepted: January 4, 2013

© 2013 The Korean Society of Pathologists/The Korean Society for Cytopathology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Background
    Gastric cancers with microsatellite instabilities (MSI) have been reported to be associated with favorable prognosis. However, the significance of the effect of MSI on the clinicopathological features, as well as its association with mucin phenotype, remains unclear.
  • Methods
    MSI status was assessed in 414 cases of gastric cancer using polymerase chain reaction analysis of five microsatellite loci, as recommended by National Cancer Institution criteria. The expression of mucins (MUC5AC, MUC6, MUC2, and CD10) was assessed.
  • Results
    Out of 414 total cases of gastric cancer, 380 (91.7%), 11 (2.7%), and 23 (5.6%) were microsatellite stable (MSS), low-level MSI (MSI-L), and high-level MSI (MSI-H), respectively. Compared to MSS/MSI-L, MSI-H gastric cancers were associated with older age (p=0.010), tumor size (p=0.014), excavated gross (p=0.042), intestinal type (p=0.028), aggressive behaviors (increase of T stage [p=0.009]), perineural invasion [p=0.022], and lymphovascular emboli [p=0.027]). MSI-H gastric cancers were associated with tumor necrosis (p=0.041), tumor-infiltrating lymphocytes (≥2/high power field, p<0.001), expanding growth patterns (p=0.038), gastric predominant mucin phenotypes (p=0.028), and MUC6 expression (p=0.016). Tumor necrosis (≥10% of mass, p=0.031), tumor-infiltrating lymphocytes (p<0.001), intestinal type (p=0.014), and gastric mucin phenotypes (p=0.020) could represent independent features associated with MSI-H gastric cancers. MSI-H intestinal type gastric cancers had a tendency for poor prognosis in univariate analysis (p=0.054) but no association in Cox multivariate analysis (p=0.197).
  • Conclusions
    Our data suggest that MSI-H gastric cancers exhibit distinct aggressive biologic behaviors and a gastric mucin phenotype. This contradicts previous reports that describe MSI-H gastric cancer as being associated with favorable prognosis.
Gastric cancer is one of the most prevalent malignancies and represents the second most common cause of cancer death worldwide.1 Microsatellite instability (MSI) is characterized by length mutations in tandem oligonucleotide repeats that are associated with defective DNA mismatch repair.2 In order to standardize MSI classification, a panel of microsatellite loci were established to test for MSI, including mononucleotide (BAT25 and BAT26) and dinucleotide (D2S123, D5S346, and D17S25) repeats (National Cancer Institute [NCI] Bethesda guidelines).3 Based on these NCI guidelines, MSI status is classified as high-level MSI (MSI-H), low-level MSI (MSI-L), or microsatellite stable (MSS). Gastric cancer with microsatellite instability (MSI-H) is reported to display distinct clinical and molecular features compared to MSS gastric cancer.4-7 MSI-H gastric cancer is associated with defective DNA mismatch repair (MMR) in cancer and inactivation of MMR genes (hMLH1 and hMSH2) by mutation or methylation.6
MSI-H colorectal cancers have been demonstrated to have better overall survival compared to MSS colorectal cancers.8 Histopathologic findings such as poor differentiation, mucinous histology, right-sided location, increased tumor-infiltrating lymphocytes (TILs), and prominent lymphoid aggregates at the advancing edge (Crohn's-like reaction) are also commonly used to predict MSI-H in colorectal cancers.9-11 In contrast to MSI-H colorectal cancers, the clinical significance of MSI status in gastric cancer remains controversial. Some investigators have reported that MSI-H gastric cancer is associated with distinct clinicopathological features (intestinal type, older age, distal tumor location, and lower incidence of lymph node metastasis) and better overall prognosis.4-7 However, other studies have reported no significant relationship between MSI status and clinical outcomes.12-14 Furthermore, there have been few reports on the utility of histopathological features to predict MSI status in gastric cancer, similar to colorectal cancers, as well the association of MSI with mucin phenotypes.15 Therefore, we investigated MSI status and its possible relationships with clinicopathological features, patient overall survival, mucin expression, and phenotypes in a large series of gastric cancers (414 gastric cancers in a high-risk population in Korea). We also analyzed the utility of histopathologic features to characterize MSI-H gastric cancer using logistic regression analysis.
Clinicopathological and survival analyses in gastric cancer
We studied a cohort of 414 gastric cancer patients who underwent gastrectomy with lymph node dissection at Pusan National University Hospital (PNUH) between 2005 and 2007, which was same cohort previously published. The group comprised 288 males and 126 females with a mean age of 59.0 years (range, 42 to 75 years). Standard formalin-fixed and paraffin-embedded sections were obtained from the Department of Pathology, PNUH, and the National Biobank of Korea, PNUH. The Institutional Review Board of PNUH approved this study. None of the patients received preoperative radiotherapy and/or chemotherapy. We assessed the following clinicopathological factors according to the Korean Standardized Pathology Report for Gastric Cancer as well as the American Joint Committee on Cancer Staging Manual, 7th edition: site, gross type, tumor size, depth of invasion, histological classification (i.e., intestinal or diffuse), and lymphovascular invasion.16-18 To monitor clinical outcomes, patients were followed up from the date of surgery to the date of death or January 1, 2012. The follow-up period ranged from approximately 1-82 months (mean, 52.9 months). The cases lost to follow-up or death from any cause other than gastric cancer were designated censored data and were not included in our analysis of survival rates.
We assessed the following histopathological features by examination of standard hematoxylin and eosin stained slides: 1) extent of tumor necrosis, <10% vs. ≥10% of tumor mass, 2) proportion of extracellular mucin formation, <10% vs. ≥10% of tumor mass, 3) presence of Crohn's-like reaction (a minimum of three lymphoid aggregates), 4) TILs, <2/high power field (HPF) vs. ≥2/HPF, and 5) growth pattern of tumor at the advancing edge (expanding, infiltrative, or mixed).
Immunohistochemical staining for mucin phenotypes
Sections were dewaxed and rehydrated according to standard procedure and washed with phosphate buffered saline (PBS). For immunohistochemical staining, sections were heated twice in a 600-W microwave oven, for 5 minutes each, in 0.01 M citrate buffer (pH 6.0). Sections were immersed in 3% H2O2 to quench endogenous peroxidase activity, and unspecified binding was blocked in 5% normal goat serum (0.1% bovine serum albumin in PBS). Immunohistochemical staining was performed using the avidin-biotin peroxidase complex method with aminoethylcarbazole as a chromogen using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. Sections were counterstained with Mayer's hematoxylin solution. Immunohistochemical staining was carried out using monoclonal antibodies against the mucin antigens (Table 1).
MUC5AC and MUC6 reflect gastric phenotypes and are markers for gastric foveolar cells and antral/cardiac mucous glandular cells, respectively. MUC2 and CD10 exhibit the typical intestinal epithelial cell phenotype and are markers for goblet cells and the brush border of intestinal absorptive epithelial cells, respectively. Adenocarcinomas with at least 10% reactivity for each mucin were identified as positive. On the basis of the combination of positive staining for MUC5AC, MUC2, MUC6, and CD10, the cases were further subdivided into gastric mucin predominant (GC-GPs), intestinal mucin predominant (GC-IPs), and null phenotype, as described previously.19
Microsatellite analysis
The DNA of cancerous tissue and the corresponding normal gastric mucosa were obtained from formalin-fixed and paraffin-embedded surgical blocks. The DNA was extracted by proteinase K digestion and the phenol-chloroform procedure. The extracted DNA was amplified by polymerase chain reaction (PCR) with fluorescent dye-labeled primers targeting five microsatellite loci: BAT25, BAT26, D5S346, D2S123, and D17S250, as recommended by the NCI guidelines.3 DNA was detected using a temperature-controlled DNA sequencer (PRISM 377, Perkin-Elmer Corp., Foster City, CA, USA), and fragment analyses were carried out with GeneScan software (Perkin-Elmer Corp.). MSI status was determined by size variation and the presence of additional bands in the PCR product from tumor DNA that were not observed in the DNA from normal tissue from the same patients (Fig. 1). In accordance with the NCI criteria,3 MSI-H was defined as instability in at least two of the five microsatellite loci; MSI-L as instability in only one locus; and MSS when none of the loci were shifted.
Statistical analysis
Clinicopathological features were analyzed by Student's t-test, the χ2 test, or Fisher's exact test to determine differences between MSI-H vs. MSS and MSI-L status. Histopathological factors associated with MSI-H gastric cancers were identified using the binary logistic regression analysis. Cumulative survival plots were obtained using the Kaplan-Meier method, and significance was compared using the log-rank test. Prognostic factors were identified using the Cox regression stepwise method (proportional hazard model) adjusted for the patient age, tumor site, depth of invasion, and lymph node metastasis. Statistical significance was set at p<0.05. Statistical calculations were performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA).
MSI-H gastric cancer was associated with increased aggressive behavior
Of the 414 gastric cancers examined, 380 (91.7%), 11 (2.7%), and 23 cases (5.6%) were MSS, MSI-L, and MSI-H, respectively, based on the NCI criteria (Table 2). Compared to MSS and MSI-L gastric cancers, MSI-H cancers were significantly associated with older age (p=0.010), increased tumor size (p=0.014), more excavated gross features (p=0.042), and intestinal histotypes (p=0.028). Furthermore, MSI-H gastric cancers exhibited more aggressive behaviors than MSS and MSI-L cancers, such as increased T stage (p=0.009), presence of perineural invasion (p=0.022), and lymphovascular tumor emboli (p=0.027) (Table 2). There was no significant relationship between MSI status and tumor location, gender, or lymph node metastasis.
In agreement with our finding of a positive relationship between MSI-H and increased aggressiveness (increased depth of invasion, presence of lymphovascular tumor emboli, and perineural invasion), there was a tendency for MSI-H to associate with reduced overall survival in intestinal-type gastric cancer (p=0.054), but not in overall gastric cancer (p=0.369) (Fig. 2). MSI-H intestinal-type gastric cancers were associated with poorer survival compared to MSS/MSI-L intestinal-type gastric cancers (71.0±1.6 months vs. 58.6±7.2 months). However, MSI status was not identified as an independent prognostic factor after adjusting for tumor location, depth of invasion, and lymph node status in the Cox regression proportional hazard model (p=0.197) (Table 3).
MSI-H gastric cancer was associated with TILs and gastric predominant mucin phenotypes
We examined the histopathological features that were associated with MSI and found that tumor necrosis (p=0.041), presence of TIL (≥2/HPF) (p<0.001), and expanding/mixed growth patterns (p=0.038) were associated with MSI-H gastric cancer compared to MSS/MSI-L gastric cancers (Table 4, Fig. 3). Crohn's-like lymphoid aggregates and extracellular mucin formation were not features of MSI-H gastric cancers.
Mucin expression analysis of the 414 gastric cancers determined that 35.5% (147/414), 67.4% (279/414), 44.9% (186/414), and 20.5% (85/414) were positive for MUC2, MUC5AC, MUC6, and CD10, respectively (Table 4). In contrast to MSS and MSI-L cancer, MSI-H gastric cancer was associated with MUC6 expression (p=0.024) (Fig. 3). There was no statistically significant difference in MUC5AC, MUC2, or CD10 expression between MSI-H and MSS/MSI-L gastric cancers. Based on their mucin expression patterns, gastric cancers were further subdivided into GC-GPs (248/414, 59.9%), GC-IPs (118/414, 28.5%), and null phenotypes (48/414, 11.6%). MSI-H gastric cancer demonstrated GC-GPs phenotypes compared to MSS and MSI-L gastric cancers (p=0.031) (Table 5). Using binary logistic regression analysis, we determined that tumor necrosis (≥10% of tumor mass) (p=0.031), TILs (≥2/HPF) (p<0.001), intestinal histologic type (p=0.014), and gastric predominant mucin phenotypes (p=0.020) could be considered independent features associated with MSI-H gastric cancers (Table 6).
In this study, MSI status in gastric cancers was significantly associated with tumor progression, lymphovascular and perineural invasion, and poor prognosis. Furthermore, we confirmed previous reports that stated that MSI-H gastric cancers are significantly associated with older age, increased tumor size, and intestinal histologic type. It was also revealed that tumor necrosis (≥10% of tumor mass), TILs (≥2/HPF) (p<0.001), intestinal histologic type (p=0.014), and gastric predominant mucin phenotypes (p=0.020) could represent independent features associated with MSI-H gastric cancers.
It has been reported that MSI-H cancers are associated with defects involving DNA MMR genes such as hMLH1 and hMSH2 as a result of mutations or promoter methylation.20 MSI-H colorectal cancer was reported to have good survival rates, more favorable responses to chemotherapy, and is an indicator of hereditary non-polyposis colorectal carcinoma syndrome.8,21,22 The recent discovery of impaired epithelial-to-mesenchymal transition in MSI-H colorectal cancers provides a molecular mechanism supporting the favorable prognosis of MSI-H colorectal cancers.23 Based on the clinical significance of MSI in colorectal cancers, many attempts to identify histopathologic predictors of MSI status have been conducted.9-11 In contrast to colorectal cancer, the clinical significance and role of MSI in gastric cancer remain controversial (Table 7). It has been reported that MSI-H gastric cancer is associated with older age, increased tumor size, and intestinal histologic type, which is in accordance with our data. However, there are conflicting reports of the relationship between MSI status and gastric cancer aggressiveness and survival. The present study demonstrated that, compared to MSS and MSI-L gastric cancers, MSI-H cancers exhibit aggressive behaviors (increase of T stage, presence of perineural invasion, and lymphovascular tumor emboli). Furthermore, poor survival was demonstrated for MSI-H gastric cancer in intestinal-type gastric cancers, but not in diffuse or overall gastric cancers. In accordance with our data, Oki et al.24 reported increased lymphovascular tumor emboli, and Seo et al.12 reported increased lymphatic invasion (p=0.104) and lymph node metastasis (p=0.157) in MSI-H gastric cancer compared to MSS/MSI-L gastric cancers. Recently, a study comprising a large series of gastric cancer patients demonstrated clinical significance of MSI status.24,25 An et al.25 reported the largest series of Koreans (1,990 gastric cancer patients), showing no prognostic significance of the disease. They revealed that there was no significant difference of disease-free survival between MSS/MSI-L and MSI-H gastric cancers at each clinical stage of I, II, III, and IV. Also it was reported that there were no benefits of 5-fluorouracil (5-FU)-based adjuvant chemotherapy in MSI-H gastric cancer compared to better disease-free survival in the MSS/MSI-L gastric cancers.25 Oki et al.24 reported that MSI status has no significant effect on overall survival or response to 5-FU in gastric cancer. These conflicting reports render it difficult to reach a conclusion regarding the effect of MSI in gastric cancer and are in contrast to the consensus data that point to a favorable prognosis in MSI-H colorectal cancers. We speculate that the reasons for this difference might be due to the high heterogeneity of gastric cancer in terms of morphological, phenotypic, and molecular aspects.
Gastric cancer is usually divided into two groups based on the tendency of gland formation: intestinal (differentiated) and diffuse (undifferentiated). It was reported that intestinal- and diffuse-type gastric cancers demonstrate different phenotypic and molecular features.26-28 In addition, there is the possibility of gastric cancer type being influenced by different types and numbers of microsatellite markers (2-10 markers), as well as ethnic differences (tendency of lower MSI-H gastric cancer prevalence in Asians [commonly <10% of all gastric cancer cases]) (Table 6). In accordance with previous studies,29,30 our study demonstrated that MUC6-positive or gastric mucin-phenotype gastric cancers were associated with MSI-H gastric cancer. Compared to previous reports that limited data to intestinal-type early gastric cancer30 or intestinal-type gastric cancer,29 we investigated a large series of all gastric cancer types (intestinal+diffuse types) and demonstrated the importance of MUC6 or gastric mucin phenotypes in view of MSI status in gastric cancer. Furthermore, we investigated histopathologic parameters associated with MSI status of gastric cancers. We found that tumor necrosis, expanding growth pattern, and TILs were associated with MSI-H gastric cancers. Unlike in colorectal cancers, poor differentiation (diffuse-type morphology), extracellular mucin, and prominent lymphoid aggregates at advancing edge (Crohn's-like reaction) were not associated with MSI status in gastric cancer.9-11 We assume that these differences are associated with different roles of MSI between gastric and colorectal cancers. Further analysis on a defined patient population will be required to achieve consensus on the utility of microsatellite repeats as predictive markers of prognosis and response to chemotherapy in gastric cancer.
This study was supported by a two-year research grant of Pusan National University. The biospecimens for this study were provided by the Pusan National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All samples derived from the National Biobank of Korea were obtained with informed consent under Institutional Review Board-approved protocols.

No potential conflict of interest relevant to this article was reported.

  • 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917. PMID: 21351269. ArticlePubMed
  • 2. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996; 56: 4836–4840. PMID: 8895729. PubMed
  • 3. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248–5257. PMID: 9823339. PubMed
  • 4. Yamamoto H, Perez-Piteira J, Yoshida T, et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999; 116: 1348–1357. PMID: 10348818. ArticlePubMed
  • 5. Lee HS, Choi SI, Lee HK, et al. Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol 2002; 15: 632–640. PMID: 12065777. ArticlePubMed
  • 6. Falchetti M, Saieva C, Lupi R, et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925–932. PMID: 18440592. ArticlePubMed
  • 7. Beghelli S, de Manzoni G, Barbi S, et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006; 139: 347–356. PMID: 16546499. ArticlePubMed
  • 8. Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921–928. PMID: 11040179. ArticlePubMed
  • 9. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527–535. PMID: 11159189. ArticlePubMedPMC
  • 10. Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M. Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. Am J Clin Pathol 2008; 129: 238–244. PMID: 18208804. ArticlePubMed
  • 11. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009; 33: 126–133. PMID: 18830122. ArticlePubMedPMC
  • 12. Seo HM, Chang YS, Joo SH, et al. Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype. J Surg Oncol 2009; 99: 143–147. PMID: 19117018. ArticlePubMed
  • 13. An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11(2 Pt 1):656–663. PMID: 15701853. ArticlePubMedPDF
  • 14. Wirtz HC, Müller W, Noguchi T, et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res 1998; 4: 1749–1754. PMID: 9676851. PubMed
  • 15. Mizoshita T, Tsukamoto T, Cao X, et al. Microsatellite instability is linked to loss of hMLH1 expression in advanced gastric cancers: lack of a relationship with the histological type and phenotype. Gastric Cancer 2005; 8: 164–172. PMID: 16086119. ArticlePubMed
  • 16. Kim WH, Park CK, Kim YB, et al. A standardized pathology report for gastric cancer. Korean J Pathol 2005; 39: 106–113.
  • 17. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101–112. PMID: 21573743. ArticlePubMedPDF
  • 18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 2009; 7th ed. New York: Springer.
  • 19. Tsukashita S, Kushima R, Bamba M, Sugihara H, Hattori T. MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer 2001; 94: 166–170. PMID: 11668493. ArticlePubMed
  • 20. Wu MS, Lee CW, Shun CT, et al. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 2000; 27: 403–411. PMID: 10719371. ArticlePubMed
  • 21. Jass JR. Diagnosis of hereditary non-polyposis colorectal cancer. Histopathology 1998; 32: 491–497. PMID: 9675586. ArticlePubMed
  • 22. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996; 69: 38–43. PMID: 8600057. ArticlePubMed
  • 23. Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010; 138: 1406–1417. PMID: 20026115. ArticlePubMed
  • 24. Oki E, Kakeji Y, Zhao Y, et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009; 16: 2510–2515. PMID: 19565284. ArticlePubMed
  • 25. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131: 505–511. PMID: 21898388. ArticlePubMed
  • 26. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49. PMID: 14320675. PubMed
  • 27. Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gann 1968; 59: 251–258. PMID: 5726267. PubMed
  • 28. Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1: 31–50. PMID: 11957042. ArticlePubMed
  • 29. Yamazaki K, Tajima Y, Makino R, et al. Tumor differentiation phenotype in gastric differentiated-type tumors and its relation to tumor invasion and genetic alterations. World J Gastroenterol 2006; 12: 3803–3809. PMID: 16804962. ArticlePubMedPMC
  • 30. Shin N, Kim HY, Kim WK, et al. Molecular biological characteristics of differentiated early gastric cancer on the basis of mucin expression. Korean J Pathol 2011; 45: 69–78. Article
Fig. 1
Microsatellite status is determined by size variation and the occurrence of additional bands (arrows) in the polymerase chain reaction product from tumor DNA (B) that are not observed in the analysis of DNA from normal tissue (A) from the same patients.
Fig. 2
Overall survival rates according to microsatellite status for all gastric cancers (A) and intestinal-type gastric cancers (B). High-level microsatellite instability (MSI-H) gastric cancer is associated with reduced survival compared to microsatellite stable (MSS)/low-level MSI (MSI-L) gastric cancers in intestinal-type gastric cancers.
Fig. 3
High-level microsatellite instability gastric cancer exhibits increased tumor-infiltrating lymphocytes (arrow) (A) and cytoplasmic positivity for MUC6 mucin expression (B).
Table 1.
Primary antibodies used in this study
Primary antibody (clone) Source Dilution
MUC2 (CLH2) Novocastra Laboratories, Newcastle, UK 1 : 500
MUC5AC (CLH5) Novocastra Laboratories, Newcastle, UK 1 : 500
MUC6 (Ccp58) Novocastra Laboratories, Newcastle, UK 1 : 500
CD10 (56C6) Novocastra Laboratories, Newcastle, UK 1 : 100
Table 2.
Clinicopathologic characteristics and MSI status in 414 gastric cancers
No. of cases MSI status
Age (yr) 58.59 ± 11.22 64 ± 11.00 0.010
 Male 288 270 (93.8) 18 (6.2) 0.419
 Female 126 121 (96.0) 5 (4.0)
Tumor size (cm) 3.77 ± 2.64 5.18 ± 3.01 0.014
 Upper/Middle 195 188 (96.4) 7 (3.6) 0.140
 Lower 219 204 (94.4) 15 (5.6)
Invasion depth (+)
 T1 225 219 (97.3) 6 (2.7) 0.009a
 T2 50 47 (94.0) 3 (6.0)
 T3 86 78 (90.7) 8 (9.3)
 T4 53 48 (90.6) 5 (9.4)
Gross type
 Elevated 105 96 (91.4) 9 (8.6) 0.042
 Flat/Depressed 180 176 (97.8) 4 (2.2)
 Excavated 129 120 (93.0) 9 (7.0)
Histologic type
 Intestinal 237 219 (92.4) 18 (7.6) 0.028b
 Diffuse 162 158 (98.1) 4 (1.9)
 Mixed 15 14 (93.3) 1 (6.7)
Lymphovascular emboli
 Negative 261 252 (96.6) 9 (3.4) 0.027
 Positive 153 140 (91.5) 13 (8.5)
Perineural invasion
 Negative 280 270 (96.4) 10 (3.6) 0.022
 Positive 134 122 (91.0) 12 (9.0)
Lymph node metastasis
 Negative 246 236 (95.9) 10 (4.1) 0.170
 Positive 168 156 (92.9) 12 (7.1)

MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, low-level MSI; MSI-H, high-level MSI.

a Between T1 vs. T2+T3+T4;

b Between intestinal type+mixed type vs. diffuse type.

Table 3.
Multivariate survival analysis with Cox regression model in intestinal type of gastric cancers
Variables B SE HR (95% CI) p-value
Age (≤ 59 yr vs >59 yr) -0.213 0.335 0.808 (0.419-1.588) 0.525
Depth (EGC vs AGC) -0.516 0.400 0.597 (0.273-1.308) 0.198
Site (upper and middle vs lower) 0.580 0.380 1.785 (0.847-3.761) 0.128
LN metastasis ([+] vs [-]) -1.140 0.398 0.320 (0.147-0.698) 0.004
MSI (MSI-H vs MSS/MSI-L) -0.582 0.451 0.559 (0.231-1.353) 0.197

B, coefficient; SE, standard error; HR, hazard ratio; CI, confidence interval; EGC, early gastric cancer; AGC, advanced gastric cancer; LN, lymph node; MSI, microsatellite instability; MSI-H, high-level MSI; MSS, microsatellite stable; MSI-L, low-level MSI.

Table 4.
Relationship between MSI status and histopathologic features in 414 gastric cancers
No. of cases MSI status
Tumor necrosis (%)
 < 10 388 370 (95.4) 18 (4.6) 0.041
 ≥ 10 26 22 (84.6) 4 (15.4)
Crohn’s-like reaction
 Absent 208 199 (95.7) 9 (4.3) 0.368
 Present 206 193 (93.7) 13 (6.3)
Extracellular mucin (%)
 < 10 366 345 (94.3) 21 (5.7) 0.289
 ≥ 10 48 47 (97.9) 1 (2.1)
Tumor infiltrating lymphocytes
 < 2/HPF 337 327 (97.0) 10 (3.0) < 0.001
 ≥ 2/HPF 77 65 (84.4) 12 (15.6)
Growth pattern
 Expanding+mixed 179 162 (90.5) 17 (9.5) 0.038
 Infiltrative 103 100 (97.1) 3 (2.9)

MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, low-level MSI; MSI-H, high-level MSI; HPF, high power filed.

Table 5.
Relationship between MSI status and mucin phenotypes and mucin expression in 414 gastric cancers
No. of cases MSI status
MUC2 (%)
 < 10 267 254 (95.1) 13 (4.9) 0.586
 ≥ 10 147 138 (93.9) 9 (6.1)
MUC5AC (%)
 < 10 135 131 (97.0) 4 (3.0) 0.138
 ≥ 10 279 261 (93.5) 18 (6.5)
MUC6 (%)
 < 10 228 221 (96.9) 7 (3.1) 0.024
 ≥ 10 186 170 (91.9) 16 (8.1)
CD10 (%)
 < 10 329 309 (93.9) 20 (6.1) 0.275
 ≥ 10 85 83 (97.6) 2 (2.4)
Mucin phenotype
 GCGP 248 230 (92.7) 18 (7.3) 0.031
 GCIP+null 168 162 (97.6) 4 (2.4)

MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, low-level MSI; MSI-H, high-level MSI; GCGP, gastric cancer with gastric mucin predominant type; GCIP, gastric cancer with intestinal mucin predominant type.

Table 6.
Histopathologic features associated with MSI-H gastric cancers
Variables B SE OR (95% CI) p-value
Tumor necrosis ( ≥ 10% vs < 10%) 1.415 0.657 4.118 (1.135-14.937) 0.031
TILs ( ≥ 2/HPF vs < 2/HPF) 1.877 0.472 6.535 (2.591-16.486) <0.001
Lauren classification (intestinal+mixed vs diffuse) 1.597 0.647 4.938 (1.388-17.566) 0.014
Mucin phenotypes (GC-GP vs GC-IP+null) 1.356 0.583 3.881 (1.238-12.170) 0.020

The clinicopathologic factors for MSI-H gastric cancers are analyzed by binary logistic regression analysis (backward, stepwise).

MSI-H, high-level microsatellite instability; B, coefficient; SE, standard error; OR, odds ratio; CI, confidence interval; TIL, tumor-infiltrating lymphocytes; HPF, high power field; GC-GP, gastric cancer with gastric mucin predominant type; GC-IP, gastric cancer with intestinal mucin predominant type.

Table 7.
Reproted datasets on the microsatellite instability and survival in gastric cancer
Authors (yr) n Markers Methods MSI-H (%) Survival
Present study 414 BAT25, BAT26, D5S346, D2S123, D17S250 Fluorescence 5.6 MSI-H have poor survival in intestinal type gastric cancer
An et al. [25] (2012) 1,990 BAT25, BAT26, D5S346, D2S123, D17S250 Fluorescence 8.5 No correlation
Oki et al. [24] (2009) 240 D2S123, D5S107, D10S197, D11S904, D13S175 Fluorescence 9.4 No correlation
Seo et al. [12] (2009) 328 BAT25, BAT26, D5S346, D2S123, D17S250 Fluorescence 8.2 No correlation
Falchetti et al. [6] (2008) 159 BAT25, BAT26, D1S104, D2S123,D3S1611, D5S107, D17S261, D18S342 Fluorescence 17.0 MSI-H have good survival in gastric cancer
Beghelli et al. [7] (2006) 510 BAT25, BAT26 Fluorescence 16 MSI-H have good survival in gastric cancer
An et al. [13] (2006) 83 BAT25, BAT26, D5S346, D2S123, D17S250 Fluorescence 19 No correlation
Lee et al. [5] (2002) 327 BAT25, BAT26 Fluorescence 9.5 MSI-H have good survival in advanced gastric cancer
Yamamoto et al. [4] (1999) 205 BAT25, AP△3, D1S158, D8S199, D5S421 Radiolabelled 14 MSI-H have good survival in advanced gastric cancer
Wirtz et al. [14] (1998) 126 BAT25, BAT26, D2S119, D2S123, D5S107, D5S346, D10S197, D11S904, D17S261, D18S34 Radiolabelled 12.8 No correlation

MSI-H, high-level microsatellite instability.

Figure & Data



    Citations to this article as recorded by  
    • Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer
      Sung Hak Lee, Yujin Lee, Hyun‐Jong Jang
      International Journal of Cancer.2023; 152(2): 298.     CrossRef
    • Genomic and Immunologic Markers of Intrinsic Resistance to Pembrolizumab Monotherapy in Microsatellite Instability-High Gastric Cancer: Observations from a Prospective Phase II Study
      Haibo Qiu
      Global Medical Genetics.2022; 09(02): 060.     CrossRef
    • Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan
      Tsutomu Yoshida, Go Ogura, Mikiko Tanabe, Takuo Hayashi, Chiho Ohbayashi, Mizutomo Azuma, Chikara Kunisaki, Yoichi Akazawa, Soji Ozawa, Sohei Matsumoto, Takayoshi Suzuki, Akira Mitoro, Tetsu Fukunaga, Akiko Shimizu, Go Fujimoto, Takashi Yao
      Cancer Biology & Therapy.2022; 23(1): 191.     CrossRef
    • Development of Tissue-Agnostic Treatments for Patients with Cancer
      Steven Lemery, Lola Fashoyin-Aje, Leigh Marcus, Sandra Casak, Julie Schneider, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A. Beaver
      Annual Review of Cancer Biology.2022; 6(1): 147.     CrossRef
    • A multicenter study on the preoperative prediction of gastric cancer microsatellite instability status based on computed tomography radiomics
      Xiuqun Liang, Yinbo Wu, Ying Liu, Danping Yu, Chencui Huang, Zhi Li
      Abdominal Radiology.2022; 47(6): 2036.     CrossRef
    • Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
      Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li
      Journal for ImmunoTherapy of Cancer.2022; 10(6): e004703.     CrossRef
    • Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab
      Akinobu Wakasugi, Akinori Sasaki, Risa Okamoto, Yasuaki Motomura
      International Cancer Conference Journal.2022; 12(1): 59.     CrossRef
    • Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer
      Xiao-Li Wei, Jian-Ying Xu, De-Shen Wang, Dong-Liang Chen, Chao Ren, Jia-Ning Li, Feng Wang, Feng-Hua Wang, Rui-Hua Xu
      Therapeutic Advances in Medical Oncology.2021; 13: 175883592198899.     CrossRef
    • Clinical and morphological portrait of tumors with microsatellite instability
      A. A. Musaelyan, V. D. Nazarov, A. S. Budnikova, S. V. Lapin, S. L. Vorobyev, V. L. Emanuel, A. A. Zakharenko, S. V. Orlov
      Advances in Molecular Oncology.2021; 8(2): 52.     CrossRef
    • How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
      Michele Ghidini, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco, Shelize Khakoo
      Journal of Clinical Medicine.2021; 10(7): 1412.     CrossRef
    • Microsatellite instability in Gastric Cancer: Between lights and shadows
      Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano
      Cancer Treatment Reviews.2021; 95: 102175.     CrossRef
    • Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy
      Zhenghao Cai, Junjun Ma, Shuchun Li, Abe Fingerhut, Jing Sun, Lu Zang, Chao Yan, Wentao Liu, Zhenggang Zhu, Minhua Zheng
      Journal of Surgical Oncology.2021;[Epub]     CrossRef
    • A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer
      Zhenghao Cai, Haiqin Song, Abe Fingerhut, Jing Sun, Junjun Ma, Luyang Zhang, Shuchun Li, Chaoran Yu, Minhua Zheng, Lu Zang
      BMC Cancer.2021;[Epub]     CrossRef
    • Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer
      Minsuk Kwon, Minae An, Samuel J. Klempner, Hyuk Lee, Kyoung-Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min, Tae Jun Kim, Byung-Hoon Min, Woong-Yang Park, Won Ki Kang, Kyu-Tae Kim, Seung Tae Kim, Jeeyun Lee
      Cancer Discovery.2021; 11(9): 2168.     CrossRef
    • Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article
      Alexander R. Siebenhüner, Sara De Dosso, Daniel Helbling, Christoforos Astaras, Petr Szturz, Peter Moosmann, Stefanie Pederiva, Thomas Winder, Philippe Von Burg, Markus Borner
      Oncology Research and Treatment.2021; 44(9): 485.     CrossRef
    • High homogeneity of mismatch repair deficiency in advanced prostate cancer
      Christoph Fraune, Ronald Simon, Doris Höflmayer, Katharina Möller, David Dum, Franziska Büscheck, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Andrea Hinsch, Eike Burandt, Till Sebastian Clauditz, Waldemar Wilczak, Guido Sauter, Stefan Steu
      Virchows Archiv.2020; 476(5): 745.     CrossRef
    • High homogeneity of MMR deficiency in ovarian cancer
      Christoph Fraune, Janina Rosebrock, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Franziska Büscheck, Doris Höflmayer, Barbara Schmalfeldt, Volkmar Müller, Linn Wölber, Isabell Witzel, Peter Paluchowski, Christian Wilke, Uwe He
      Gynecologic Oncology.2020; 156(3): 669.     CrossRef
    • Molecular Classification of Gastric Cancer among Alaska Native People
      Holly Martinson, Dominic Mallari, Christine Richter, Tsung-Teh Wu, James Tiesinga, Steven Alberts, Matthew Olnes
      Cancers.2020; 12(1): 198.     CrossRef
    • Tumor immune response and immunotherapy in gastric cancer
      Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee
      Journal of Pathology and Translational Medicine.2020; 54(1): 20.     CrossRef
    • MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass
      Christoph Fraune, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Christian Kähler, Martina Kluth, Doris Höflmayer, Franziska Büscheck, David Dum, Andreas M. Luebke, Eike Burandt, Till Sebastian Clauditz, Waldemar Wilczak, Guido Sauter, Stefan
      Urologic Oncology: Seminars and Original Investigations.2020; 38(5): 488.     CrossRef
    • MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
      Christoph Fraune, Eike Burandt, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Franziska Büscheck, Doris Höflmayer, Niclas Ch. Blessin, Tim Mandelkow, Wenchao Li, Daniel Perez, Jakob R. Izbicki, Waldemar Wilczak, Guido Sauter, J
      Annals of Surgical Oncology.2020; 27(10): 3997.     CrossRef
    • CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
      Jerry B. Harvey, Luan H. Phan, Oscar E. Villarreal, Jessica L. Bowser
      Frontiers in Immunology.2020;[Epub]     CrossRef
    • Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
      Zhihao Lu, Huan Chen, Shuang Li, Jifang Gong, Jian Li, Jianling Zou, Lihong Wu, Jianing Yu, Wenbo Han, Huaibo Sun, Xi Jiao, Xiaotian Zhang, Zhi Peng, Ming Lu, Zhenghang Wang, Henghui Zhang, Lin Shen
      Journal for ImmunoTherapy of Cancer.2020; 8(2): e000374.     CrossRef
    • Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray
      Chong Zhao, Zhiqiang Feng, Hongzhen He, Dan Zang, Hong Du, Hongli Huang, Yanlei Du, Jie He, Yongjian Zhou, Yuqiang Nie, Girijesh Kumar Patel
      PLOS ONE.2020; 15(10): e0238836.     CrossRef
    • Clinicopathologic Characteristics and Long-Term Outcome of Gastric Cancer Patients with Family History: Seven-Year Follow-Up Study for Korean Health Check-Up Subjects
      Jooyoung Lee, Su Jin Chung, Ji Min Choi, Yoo Min Han, Joo Sung Kim, Greger Lindberg
      Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
    • Implication of expression of MMR proteins and clinicopathological characteristics in gastric cancer
      Renu Verma, Puja Sakhuja, Ritu Srivastava, Prakash Chand Sharma
      Asia-Pacific Journal of Oncology.2020; : 1.     CrossRef
    • Prognostic significance of microsatellite‐instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy
      Georg Martin Haag, Elena Czink, Aysel Ahadova, Thomas Schmidt, Leila Sisic, Susanne Blank, Ulrike Heger, Leonidas Apostolidis, Anne Katrin Berger, Christoph Springfeld, Felix Lasitschka, Dirk Jäger, Magnus Knebel Doeberitz, Matthias Kloor
      International Journal of Cancer.2019; 144(7): 1697.     CrossRef
    • Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
      Zhihao Lu, Jianling Zou, Ying Hu, Shuang Li, Tao Zhou, Jifang Gong, Jian Li, Xiaotian Zhang, Jun Zhou, Ming Lu, Xicheng Wang, Zhi Peng, Changsong Qi, Yanyan Li, Jie Li, Yan Li, Jianyin Zou, Xiao Du, Henghui Zhang, Lin Shen
      JAMA Network Open.2019; 2(7): e197621.     CrossRef
    • Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
      Carolina Martinez-Ciarpaglini, Tania Fleitas-Kanonnikoff, Valentina Gambardella, Marta Llorca, Cristina Mongort, Regina Mengual, Gema Nieto, Lara Navarro, Marisol Huerta, Susana Rosello, Desamparados Roda, Noelia Tarazona, Samuel Navarro, Gloria Ribas, An
      ESMO Open.2019; 4(3): e000470.     CrossRef
    • The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
      Gagandeep Brar, Manish A. Shah
      Therapeutic Advances in Gastroenterology.2019; 12: 175628481986976.     CrossRef
    • Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
      Alessandro Cavaliere, Valeria Merz, Simona Casalino, Camilla Zecchetto, Francesca Simionato, Hayley Louise Salt, Serena Contarelli, Raffaela Santoro, Davide Melisi
      Journal of Gastric Cancer.2019; 19(4): 375.     CrossRef
      D. L. Rotin, O. V. Paklina, I. O. Tin’kova, D. N. Grekov
      Russian Journal of Biotherapy.2019; 18(4): 17.     CrossRef
    • Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
      K Polom, L Marano, D Marrelli, R De Luca, G Roviello, V Savelli, P Tan, F Roviello
      British Journal of Surgery.2018; 105(3): 159.     CrossRef
    • Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes
      Chae H Kwon, Young K Kim, Sojeong Lee, Ahrong Kim, Hye J Park, Yuri Choi, Yeo J Won, Do Y Park, Gregory Y Lauwers
      Histopathology.2018; 72(4): 556.     CrossRef
    • Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
      Margherita Ratti, Andrea Lampis, Jens C. Hahne, Rodolfo Passalacqua, Nicola Valeri
      Cellular and Molecular Life Sciences.2018; 75(22): 4151.     CrossRef
    • High-throughput Protein and mRNA Expression–based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications
      Sangjeong Ahn, So-Jeong Lee, Yonugkeum Kim, Ahrong Kim, Nari Shin, Kyung Un Choi, Chang-Hun Lee, Gi Yeong Huh, Kyong-Mee Kim, Namrata Setia, Gregory Y. Lauwers, Do Youn Park
      American Journal of Surgical Pathology.2017; 41(1): 106.     CrossRef
    • Molecular Testing for Gastrointestinal Cancer
      Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
      Journal of Pathology and Translational Medicine.2017; 51(2): 103.     CrossRef
    • Molecular testing of gastrointestinal tumours
      Matthew Evans, Matthew Smith, Brendan O'Sullivan, Philippe Taniere
      Diagnostic Histopathology.2017; 23(10): 442.     CrossRef
    • Gastric Carcinomas With Lymphoid Stroma
      Raul S Gonzalez, Justin M M Cates, Frank Revetta, Loralee A McMahon, Kay Washington
      American Journal of Clinical Pathology.2017; 148(6): 477.     CrossRef
    • Meta-Analysis of Prognostic Role of Ki-67 Labeling Index in Gastric Carcinoma
      Jung-Soo Pyo, Nae Yu Kim
      The International Journal of Biological Markers.2017; 32(4): 447.     CrossRef
    • Tissue-Agnostic Drug Development
      Keith T. Flaherty, Dung T. Le, Steven Lemery
      American Society of Clinical Oncology Educational Book.2017; (37): 222.     CrossRef
    • Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
      Mi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hye Kyung Lee, Ho Suk Kang, Kyueng-Whan Min
      Oncotarget.2017; 8(47): 82399.     CrossRef
    • Hypermutation and microsatellite instability in gastrointestinal cancers
      Kizuki Yuza, Masayuki Nagahashi, Satoshi Watanabe, Kazuaki Takabe, Toshifumi Wakai
      Oncotarget.2017; 8(67): 112103.     CrossRef
    • The emerging role of immunotherapy in gastric and esophageal adenocarcinoma
      Bruno Bockorny, Eirini Pectasides
      Future Oncology.2016; 12(15): 1833.     CrossRef
    • Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland
      Katarzyna Karpińska-Kaczmarczyk, Magdalena Lewandowska, Małgorzata Ławniczak, Andrzej Białek, Elżbieta Urasińska
      Medical Science Monitor.2016; 22: 2886.     CrossRef
    • Immunotherapy for Gastroesophageal Cancer
      Emily Goode, Elizabeth Smyth
      Journal of Clinical Medicine.2016; 5(10): 84.     CrossRef
    • Lauren classification and individualized chemotherapy in gastric cancer
      Oncology Letters.2016; 11(5): 2959.     CrossRef
    • High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability
      Karol Polom, Daniele Marrelli, Valeria Pascale, Giandomenico Roviello, Costantino Voglino, Henry Rho, Carla Vindigni, Mario Marini, Raffaele Macchiarelli, Franco Roviello
      Journal of Cancer Research and Clinical Oncology.2016; 142(8): 1817.     CrossRef
    • MUC2 Expression Is Correlated with Tumor Differentiation and Inhibits Tumor Invasion in Gastric Carcinomas: A Systematic Review and Meta-analysis
      Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang, Dong-Hoon Kim, Kyungeun Kim, In-Gu Do, Dong Hyun Kim
      Journal of Pathology and Translational Medicine.2015; 49(3): 249.     CrossRef
    • Correlation between microsatellite instability-high phenotype and occult lymph node metastasis in gastric carcinoma
      Jiwoon Choi, Soo Kyung Nam, Do Joong Park, Hwal Woong Kim, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
      APMIS.2015; 123(3): 215.     CrossRef
    • Clinicopathologic and molecular features associated with patient age in gastric cancer
      Ji Yeon Seo, Eun Hyo Jin, Hyun Jin Jo, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Hyun Chae Jung, Dong Ho Lee
      World Journal of Gastroenterology.2015; 21(22): 6905.     CrossRef
    • Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
      Ismael Riquelme, Kathleen Saavedra, Jaime A. Espinoza, Helga Weber, Patricia García, Bruno Nervi, Marcelo Garrido, Alejandro H. Corvalán, Juan Carlos Roa, Carolina Bizama
      Oncotarget.2015; 6(28): 24750.     CrossRef
    • A phylogenetic model for understanding the effect of gene duplication on cancer progression
      Qin Ma, Jaxk H. Reeves, David A. Liberles, Lili Yu, Zheng Chang, Jing Zhao, Juan Cui, Ying Xu, Liang Liu
      Nucleic Acids Research.2014; 42(5): 2870.     CrossRef
    • The analysis of microsatellite instability in extracolonic gastrointestinal malignancy
      Andrew S. Williams, Weei-Yuarn Huang
      Pathology.2013; 45(6): 540.     CrossRef


    JPTM : Journal of Pathology and Translational Medicine